Gemcitabine

ATC Code L01BC05

Gemcitabine

Definition

A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA. This locks DNA polymerase thereby resulting in "masked termination" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.

Also known as 1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose, 2'Deoxy-2',2'-Difluorocytidine, dFdC, dFdCyd, Difluorodeoxycytidine, GEMCITABINE — per NCIT

Also identified as

Indications

Disease Relation Source
Breast neoplasm may treat MEDRT · Public domain (U.S. Government work)
Non-small cell lung carcinoma may treat MEDRT · Public domain (U.S. Government work)
Ovarian cancer may treat MEDRT · Public domain (U.S. Government work)
Pancreatic ductal adenocarcinoma may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Alimentary part of gastrointestinal system may treat a disease of this organ DERIVED · CC BY 4.0
Exocrine pancreas may treat a disease of this organ DERIVED · CC BY 4.0
Lungs may treat a disease of this organ DERIVED · CC BY 4.0
Pancreas may treat a disease of this organ DERIVED · CC BY 4.0
Ventral pancreatic duct may treat a disease of this organ DERIVED · CC BY 4.0

5 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.